Acorda Therapeutics: all 53 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedNCT03051607Phase 3Results posted
• Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)TerminatedNCT02474407Phase 2Results posted
• Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedNCT02453386Phase 3Results posted
• Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.TerminatedNCT02422940Phase 3Results posted
• Randomized Safety Study of CVT-301 Compared to an Observational Control GroupCompletedNCT02352363Phase 3Results posted
• An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.TerminatedNCT02316847Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.CompletedNCT02271217Phase 3Results posted
• SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)CompletedNCT02258152Phase 2Results posted
• Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02242487Phase 3Results posted
• Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02240030Phase 3Results posted
• A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG TrialCompletedNCT01839279Phase 2Results posted
• AC105 in Patients With Acute Traumatic Spinal Cord InjuryTerminatedNCT01750684Phase 2Results posted
• Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT01683838Phase 3Results posted
• A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic StrokeCompletedNCT01605825Phase 2Results posted
• An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664Results posted
• Safety and Tolerability of Dalfampridine in Subjects With Cerebral PalsyCompletedNCT01468350Phase 1Results posted
• A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure EpisodeCompletedNCT01417078Phase 2Results posted
• Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral PalsyTerminatedNCT01405950Phase 1Results posted
• Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3Results posted
• Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal ImpairmentCompletedNCT01316055Phase 1Results posted
• Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart FailureCompletedNCT01258387Phase 1Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3Results posted
• Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)CompletedNCT00595231Phase 2Results posted
• Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3Results posted
• Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3Results posted
• Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2Results posted
• Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT00041717Phase 3Results posted
• Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)CompletedNCT03887884Phase 1
• Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of TozadenantTerminatedNCT03212313Phase 1
• A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug UsersTerminatedNCT03200080Phase 1
• A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation PowderCompletedNCT02905227Phase 1
• A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsCompletedNCT02812394Phase 1
• A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)CompletedNCT02807675Phase 1
• A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult VolunteersCompletedNCT02663999Phase 1
• A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking AdultsCompletedNCT02633839Phase 1
• A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With AsthmaCompletedNCT02633007Phase 1
• Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy AdultsCompletedNCT02609945Phase 1
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
• Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled TozadenantCompletedNCT02240290Phase 1
• A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart FailureCompletedNCT01944683Phase 1
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple SclerosisCompletedNCT01803867Phase 1
• Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesCompletedNCT01777555Phase 2
• Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesCompletedNCT01617135Phase 2
• Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedNCT01283594Phase 2/3
• Safety and Pharmacokinetics of ELB353 in Healthy MenCompletedNCT00977886Phase 1
• BTT1023 in PsoriasisCompletedNCT00871598Phase 1
• BTT-1023 in Rheumatoid ArthritisCompletedNCT00851240Phase 1
• Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent VolunteersCompletedNCT00656357Phase 1/2
• Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2
• ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)TerminatedNCT00439192Phase 2
• ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of TreatmentTerminatedNCT00322803Phase 2

← Acorda Therapeutics overview and focus areas